# US 2022/0034907 A1 · Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034907 A1
- Document ID: US20220034907A1
- Status: Published application
- Kind: A1
- Application number: 17/299,660
- Filed: 2019-12-03
- Published: 2022-02-03
- Earliest claimed: 2018-12-06
- Assignees: Biogen MA Inc.
- Applicants: Biogen MA Inc.
- Inventors: Toby Arlo FERGUSON; Danielle LeeZetta GRAHAM; Steve Sang-Woo HAN; Alexander Reid Vincent MCCAMPBELL; Giulio SRUBEK-TOMASSY
- Web page: https://patentgrep.com/patent/US20220034907A1

## CPC

- G01N 33/6887: {from muscle, cartilage or connective tissue}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12Q 2600/156: Polymorphic or mutational markers
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- G01N 2800/28: Neurological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

In one aspect, the invention provides a method for alleviating a symptom in a patient with amyotrophic lateral sclerosis, comprising administering an efficacious therapeutic that is efficacious to the patient, the efficacious therapeutic, when administered to the patient, resulting in a level of a neurofilament protein in a biological sample of the patient that is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the therapeutic. In some embodiments, the patient is currently being administered with or has formerly been administered with either a non-efficacious therapeutic or a therapeutic that is different than the efficacious therapeutic.

## Claims

### Claim 1

A method for alleviating a symptom in a patient with amyotrophic lateral sclerosis, comprising administering an efficacious therapeutic that is efficacious to the patient, the efficacious therapeutic, when administered to the patient, resulting in a level of a neurofilament protein in a biological sample of the patient that is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the efficacious therapeutic.

### Claim 2

A method for determining if a therapeutic administered to a patient with amyotrophic lateral sclerosis is an efficacious therapeutic that is efficacious to the patient, comprising obtaining or having obtained a biological sample from the patient administered with the therapeutic; and measuring or having measured a level of a neurofilament protein in a biological sample of the patient to obtain a post-treatment level, wherein a post-treatment level that is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the therapeutic identifies the therapeutic as being efficacious to the patient.

### Claim 3

A method for alleviating a symptom in a patient with amyotrophic lateral sclerosis by administration of an efficacious therapeutic, comprising:
(a) determining whether a symptom of amyotrophic lateral sclerosis in the patient will be alleviated by a candidate therapeutic by:
(i) obtaining or having obtained a biological sample from the patient following administration of the candidate therapeutic; and
(ii) measuring or having measured a level of a neurofilament protein in the biological sample to obtain a post-treatment level; and if the post-treatment level is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the candidate therapeutic, then the candidate therapeutic is an efficacious therapeutic and
(b) administering the efficacious therapeutic to the patient, wherein administration of the efficacious therapeutic will alleviate the symptom of amyotrophic lateral sclerosis in the patient.

### Claim 4 (depends on 1, 2)

The method of claim 1, 2, or 3 wherein the patient is currently being administered with or has formerly been administered with (a) a non-efficacious therapeutic or (b) a therapeutic that is different than the candidate therapeutic.

### Claim 5

A method for alleviating a symptom in a patient with amyotrophic lateral sclerosis by administration of an efficacious therapeutic, comprising measuring a level of a neurofilament protein in a biological sample of the patient, the patient currently being administered with a first therapeutic that is (a) a non-efficacious therapeutic or (b) different than the efficacious therapeutic and, if the level is greater than or equal to a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the efficacious therapeutic, then stopping administration of the first therapeutic to the patient and starting administration of the efficacious therapeutic to the patient.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the post-treatment level of the neurofilament protein in the biological sample of the patient administered the efficacious therapeutic is at least 10% lower than the level of the neurofilament protein in the biological sample of a patient not administered the efficacious therapeutic.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the post-treatment level of the neurofilament protein in the biological sample of the patient administered the efficacious therapeutic for at least three months is at least 10% lower than the level of the neurofilament protein in the biological sample of a patient not administered the efficacious therapeutic.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the level of the neurofilament protein in the biological sample of the patient administered the efficacious therapeutic for at least six months is at least 10% lower than the level of the neurofilament protein in the biological sample of a patient not administered the efficacious therapeutic.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the level of the neurofilament protein in the biological sample of the patient administered the efficacious therapeutic for at least twelve months is at least 10% lower than the level of the neurofilament protein in the biological sample of a patient not administered the efficacious therapeutic.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the administration of the efficacious therapeutic slows the progression of amyotrophic lateral sclerosis in the patient.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the biological sample comprises blood, serum, plasma, or cerebral spinal fluid.

### Claim 12

A method of treating amyotrophic lateral sclerosis in a human subject in need thereof, comprising:
measuring a neurofilament protein level in a first biological sample obtained from the human subject;
administering one or more doses of a therapeutic to the human subject; and
measuring a neurofilament protein level in a second biological sample obtained from the human subject after administering the one or more doses of the therapeutic, wherein the neurofilament protein level in the second biological sample is lower than the neurofilament protein level in the first biological sample.

### Claim 13 (depends on 12)

The method of claim 12, further comprising administering further doses of the therapeutic to the human subject after measuring a neurofilament protein level in the second biological sample that is lower than the neurofilament protein level in the first biological sample.

### Claim 14

A method of treating amyotrophic lateral sclerosis in a human subject in need thereof, comprising:
administering initial doses of a therapeutic to the human subject, wherein each of the initial doses is in the same amount and is administered at the same dosing interval between doses;
measuring a neurofilament protein level in a first biological sample obtained from the human subject after administering the initial doses that is lower than a neurofilament protein level measured in a second biological sample obtained from the human subject prior to administering the initial doses; and
administering further doses of the therapeutic to the human subject, wherein each of the further doses is in the same or lesser amount and at the same or lengthened dosing interval as compared to the initial doses.

### Claim 15

A method of treating amyotrophic lateral sclerosis in a human subject in need thereof, comprising:
administering initial doses of a therapeutic to the human subject, wherein each of the initial doses is in the same amount and is administered at the same dosing interval between doses;
measuring a neurofilament protein level in a first biological sample obtained from the human subject after administering the initial doses that is equal to or higher than a neurofilament protein level measured in a second biological sample obtained from the human subject prior to administering the initial doses; and
administering further doses of the therapeutic to the human subject, wherein each of the further doses is in an increased amount and/or at a shortened dosing interval as compared to the initial doses.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12 to 15, wherein the therapeutic is an antisense compound according to the following formula:
mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te (nucleobase sequence of SEQ ID NO:8), wherein,
A=an adenine,
mC=a 5-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar,
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage;
or a pharmaceutically acceptable salt thereof.

### Claim 17

The method of any one of the preceding claims, wherein the patient or the human subject has a mutation in the superoxide dismutase 1 (SOD1) gene associated with amyotrophic lateral sclerosis.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mutation in the SOD1 gene is A4V.

### Claim 19 (depends on 17)

The method of claim 17, wherein the mutation in the SOD1 gene is A4V, H46R, G93S, A4T, G141X, D133A, V148G, N139K, G85R, G93A, V14G, C6S, I113T, D49K, G37R, A89V, E100G, D90A, T137A, E100K, G41A, G41D, G41S, G13R, G72S, L8V, F20C, Q22L, H48R, T54R, 5591, V87A, T88deltaTAD, A89T, V97M, S105deltaSL, V118L, D124G, L114F, D90A, G12R, or G147R.

### Claim 20

The method of any one of the preceding claims, wherein the neurofilament protein is a neurofilament light chain.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the neurofilament protein is a neurofilament heavy chain.

### Claim 22 (depends on 21)

The method of claim 21, wherein the neurofilament heavy chain is a phosphorylated neurofilament heavy chain.

### Claim 23 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 12 to 22, wherein the first biological sample and the second biological sample comprise blood, serum, plasma, or cerebral spinal fluid.
